Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Preoperative chlorhexidine mouthwash to reduce pneumonia after cardiac surgery: A systematic review and meta-analysis.

Bardia A, Blitz D, Dai F, Hersey D, Jinadasa S, Tickoo M, Schonberger RB.

J Thorac Cardiovasc Surg. 2019 Jan 21. pii: S0022-5223(19)30066-2. doi: 10.1016/j.jtcvs.2019.01.014. [Epub ahead of print]

PMID:
30826096
2.

Intraperitoneal transplantation of bioengineered humanized liver grafts supports failing liver in acute condition.

Vishwakarma SK, Bardia A, Lakkireddy C, Raju N, Paspala SAB, Habeeb MA, Khan AA.

Mater Sci Eng C Mater Biol Appl. 2019 May;98:861-873. doi: 10.1016/j.msec.2019.01.045. Epub 2019 Jan 14.

PMID:
30813092
3.

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.

Spring LM, Wander SA, Zangardi M, Bardia A.

Curr Oncol Rep. 2019 Feb 26;21(3):25. doi: 10.1007/s11912-019-0769-3. Review.

PMID:
30806829
4.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
5.

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2019 Feb 15;25(4):1435. doi: 10.1158/1078-0432.CCR-18-4266. No abstract available.

PMID:
30770494
6.

Pigmented nipple-like nodule on the neck.

Mushtaq S, Singh S, Khera S, Bardia A.

Indian J Dermatol Venereol Leprol. 2019 Mar-Apr;85(2):235. doi: 10.4103/ijdvl.IJDVL_345_18. No abstract available.

7.

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models.

Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M.

Nat Cell Biol. 2019 Feb;21(2):190-202. doi: 10.1038/s41556-018-0256-3. Epub 2018 Dec 31.

PMID:
30598531
8.

Bioengineered functional humanized livers: An emerging supportive modality to bridge the gap of organ transplantation for management of end-stage liver diseases.

Vishwakarma SK, Lakkireddy C, Bardia A, Paspala SAB, Tripura C, Habeeb MA, Khan AA.

World J Hepatol. 2018 Nov 27;10(11):822-836. doi: 10.4254/wjh.v10.i11.822. Review.

9.

Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications.

Bardia A, Wai M, Fontes ML.

Curr Opin Anaesthesiol. 2019 Feb;32(1):80-85. doi: 10.1097/ACO.0000000000000674.

PMID:
30531609
10.

Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?

Zangardi ML, Spring LM, Nagayama A, Bardia A.

Expert Opin Investig Drugs. 2019 Feb;28(2):107-112. doi: 10.1080/13543784.2019.1555239. Epub 2018 Dec 17. Review.

PMID:
30507322
11.

Bioengineering Human Neurological Constructs Using Decellularized Meningeal Scaffolds for Application in Spinal Cord Injury.

Vishwakarma SK, Bardia A, Lakkireddy C, Paspala SAB, Khan AA.

Front Bioeng Biotechnol. 2018 Nov 1;6:150. doi: 10.3389/fbioe.2018.00150. eCollection 2018.

12.

Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer.

Bardia A, Hovnanian MD, Brachtel EF, Nardi V.

N Engl J Med. 2018 Nov 15;379(20):1946-1953. doi: 10.1056/NEJMcpc1616400. No abstract available.

PMID:
30428289
13.

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.

J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

PMID:
30339520
14.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB.

J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392. [Epub ahead of print]

PMID:
30235087
15.

Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.

Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A.

Breast Cancer Res Treat. 2018 Dec;172(3):733-740. doi: 10.1007/s10549-018-4959-8. Epub 2018 Sep 15.

PMID:
30220055
16.

Molecular dynamics of pancreatic transcription factors in bioengineered humanized insulin producing neoorgan.

Vishwakarma SK, Lakkireddy C, Bardia A, Raju N, Paspala SAB, Habeeb MA, Khan AA.

Gene. 2018 Oct 30;675:165-175. doi: 10.1016/j.gene.2018.07.006. Epub 2018 Jul 3.

PMID:
30180963
17.

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.

Princic N, Aizer A, Tang DH, Smith DM, Johnson W, Bardia A.

Curr Med Res Opin. 2018 Sep 20:1-8. doi: 10.1080/03007995.2018.1519500. [Epub ahead of print]

PMID:
30175631
18.

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.

Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S.

Cancer Discov. 2018 Oct;8(10):1286-1299. doi: 10.1158/2159-8290.CD-18-0432. Epub 2018 Aug 13.

PMID:
30104333
19.

Protective Role of Hypothermia Against Heat Stress in Differentiated and Undifferentiated Human Neural Precursor Cells: A Differential Approach for the Treatment of Traumatic Brain Injury.

Vishwakarma SK, Bardia A, Fathima N, Chandrakala L, Rahamathulla S, Raju N, Srinivas G, Raj A, Sandhya A, Satti V, Tiwari SK, Paspala SAB, Khan AA.

Basic Clin Neurosci. 2017 Nov-Dec;8(6):453-466. doi: 10.29252/NIRP.BCN.8.6.453.

20.

Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances.

Bardia A, Hurvitz S.

Clin Cancer Res. 2018 Nov 1;24(21):5206-5218. doi: 10.1158/1078-0432.CCR-18-0162. Epub 2018 Jun 8. Review.

PMID:
29884743
21.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.

Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.

PMID:
29804902
22.

Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer.

Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K.

Clin J Oncol Nurs. 2018 Jun 1;22(3):E71-E77. doi: 10.1188/18.CJON.E71-E77.

PMID:
29781452
23.

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU.

NPJ Breast Cancer. 2018 May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018.

24.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 Aug;171(1):121-129. doi: 10.1007/s10549-018-4811-1. Epub 2018 May 11.

PMID:
29752687
25.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA.

Breast Cancer Res Treat. 2018 Aug;171(1):111-120. doi: 10.1007/s10549-018-4813-z. Epub 2018 May 9.

PMID:
29744674
26.

Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.

Spring L, Bardia A.

Clin Cancer Res. 2018 Jul 1;24(13):2981-2983. doi: 10.1158/1078-0432.CCR-18-0463. Epub 2018 Apr 23.

PMID:
29685881
27.

Role of drug transporters and heat shock proteins during ethanol exposure to human neural precursor cells and its lineages.

Vishwakarma SK, Fatima N, Lakkireddy C, Raju N, Bardia A, Sandhya A, Paspala SAB, Satti V, Khan AA.

Tissue Cell. 2018 Apr;51:14-23. doi: 10.1016/j.tice.2018.02.001. Epub 2018 Feb 7.

PMID:
29622083
28.

AR Expression in Breast Cancer CTCs Associates with Bone Metastases.

Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S.

Mol Cancer Res. 2018 Apr;16(4):720-727. doi: 10.1158/1541-7786.MCR-17-0480. Epub 2018 Feb 16.

PMID:
29453314
29.

Bioengineered humanized livers as better three-dimensional drug testing model system.

Vishwakarma SK, Bardia A, Lakkireddy C, Nagarapu R, Habeeb MA, Khan AA.

World J Hepatol. 2018 Jan 27;10(1):22-33. doi: 10.4254/wjh.v10.i1.22.

30.

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology.

Vidula N, Bardia A.

Oncotarget. 2017 Nov 21;8(63):106167-106168. doi: 10.18632/oncotarget.22580. eCollection 2017 Dec 5. No abstract available.

31.

Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) in Adult Patients - Many Questions, Few Answers, and Hard Choices.

Bardia A, Schonberger RB.

J Cardiothorac Vasc Anesth. 2018 Jun;32(3):1183-1184. doi: 10.1053/j.jvca.2017.10.037. Epub 2017 Oct 31. No abstract available.

PMID:
29276089
32.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

33.

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A.

Ann Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784.

PMID:
29236940
34.

Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Nagayama A, Ellisen LW, Chabner B, Bardia A.

Target Oncol. 2017 Dec;12(6):719-739. doi: 10.1007/s11523-017-0535-0. Review.

PMID:
29116596
35.

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A.

J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223. doi: 10.6004/jnccn.2017.0158.

PMID:
28982747
36.

Enhanced neuroprotective effect of mild-hypothermia with VPA against ethanol-mediated neuronal injury.

Vishwakarma SK, Bardia A, Chandrakala L, Arshiya S, Paspala SAB, Satti V, Khan AA.

Tissue Cell. 2017 Dec;49(6):638-647. doi: 10.1016/j.tice.2017.09.004. Epub 2017 Sep 14.

PMID:
28947065
37.

Mechanism of Action and Clinical Impact of Ribociclib-Response.

Tripathy D, Bardia A, Sellers WR.

Clin Cancer Res. 2017 Sep 15;23(18):5658. doi: 10.1158/1078-0432.CCR-17-1819. No abstract available.

38.

Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

Zangardi ML, Spring LM, Blouin GC, Bardia A.

Expert Rev Clin Pharmacol. 2017 Nov;10(11):1169-1176. doi: 10.1080/17512433.2017.1376653. Epub 2017 Sep 18. Review.

PMID:
28875723
39.

Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells.

Vishwakarma SK, Sharmila P, Bardia A, Chandrakala L, Raju N, Sravani G, Sastry BVS, Habeeb MA, Khan AA, Dhayal M.

Sci Rep. 2017 Aug 17;7(1):8539. doi: 10.1038/s41598-017-08878-y.

40.

AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.

Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, Sgroi D, Loda M, Ramaswamy S.

Breast Cancer Res. 2017 Aug 1;19(1):88. doi: 10.1186/s13058-017-0877-7.

41.

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.

Spring LM, Zangardi ML, Moy B, Bardia A.

Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Review.

42.

Antibody-drug conjugates in breast cancer.

Bardia A.

Clin Adv Hematol Oncol. 2017 Apr;15(4):251-254. No abstract available.

PMID:
28591100
43.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM.

Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.

44.

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR.

J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26.

PMID:
28548889
45.

Ultrasound as a Screening Tool for Central Venous Catheter Positioning and Exclusion of Pneumothorax.

Amir R, Knio ZO, Mahmood F, Oren-Grinberg A, Leibowitz A, Bose R, Shaefi S, Mitchell JD, Ahmed M, Bardia A, Talmor D, Matyal R.

Crit Care Med. 2017 Jul;45(7):1192-1198. doi: 10.1097/CCM.0000000000002451.

PMID:
28422778
46.

Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.

Tripathy D, Bardia A, Sellers WR.

Clin Cancer Res. 2017 Jul 1;23(13):3251-3262. doi: 10.1158/1078-0432.CCR-16-3157. Epub 2017 Mar 28. Review.

47.

SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?

Spring L, Bardia A.

Lancet Oncol. 2017 May;18(5):564-565. doi: 10.1016/S1470-2045(17)30106-7. Epub 2017 Mar 15. No abstract available.

PMID:
28314690
48.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

49.

Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).

Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA.

Biomed Opt Express. 2017 Jan 4;8(2):555-569. doi: 10.1364/BOE.8.000555. eCollection 2017 Feb 1.

50.

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.

Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.

Supplemental Content

Loading ...
Support Center